Teva launches Lialda generic

Press enter to search
Close search
Open Menu

Teva launches Lialda generic

By David Salazar - 03/27/2018
Teva has introduced its Lialda generic (mesalamine delayed-release tablets). The drug is indicated to treat mild-to-moderate ulcerative colitis.

“The launch of mesalamine is a significant addition to Teva’s generic portfolio,” Teva executive vice president and head of North American Commercial Brendan O’Grady said. “With more than a million people in the U.S. estimated to suffer from inflammatory bowel diseases, including ulcerative colitis, this is an important and more affordable generic treatment option for our customers.”

Teva’s Lialda generic will be available in 1.2-g dosage strength. The product’s market size was roughly $1.11 billion for the 12 months ended January 2018, according to IQVIA data.

Related Topics